DKK 1120.0
(-2.61%)
Year | Total Debt | Total Debt Growth |
---|---|---|
2023 | - DKK | 0.0% |
2022 | - DKK | -100.0% |
2021 | 39.96 Million DKK | -43.48% |
2020 | 70.71 Million DKK | -8.29% |
2019 | 77.1 Million DKK | 0.0% |
2018 | - DKK | 0.0% |
2017 | - DKK | 0.0% |
2016 | - DKK | -100.0% |
2015 | 245 Thousand DKK | 0.0% |
2014 | 245 Thousand DKK | 24400.0% |
2013 | 1000.00 DKK | 0.0% |
Year | Total Debt | Total Debt Growth |
---|---|---|
2024 Q2 | - DKK | 0.0% |
2024 Q1 | - DKK | 0.0% |
2023 Q2 | - DKK | 0.0% |
2023 Q3 | - DKK | 0.0% |
2023 FY | - DKK | 0.0% |
2023 Q1 | - DKK | 0.0% |
2023 Q4 | - DKK | 0.0% |
2022 Q4 | - DKK | 0.0% |
2022 Q3 | - DKK | 0.0% |
2022 FY | - DKK | -100.0% |
2022 Q2 | - DKK | 0.0% |
2022 Q1 | - DKK | -100.0% |
2021 Q3 | 37.39 Million DKK | -36.18% |
2021 FY | 39.96 Million DKK | -43.48% |
2021 Q1 | 56.53 Million DKK | -20.05% |
2021 Q2 | 58.59 Million DKK | 3.63% |
2021 Q4 | 39.96 Million DKK | 6.89% |
2020 Q2 | 80.94 Million DKK | 4.09% |
2020 FY | 70.71 Million DKK | -8.29% |
2020 Q4 | 70.71 Million DKK | 5.45% |
2020 Q3 | 67.05 Million DKK | -17.15% |
2020 Q1 | 77.75 Million DKK | 0.84% |
2019 FY | 77.1 Million DKK | 0.0% |
2019 Q1 | 9.54 Million DKK | 0.0% |
2019 Q3 | 74.23 Million DKK | 678.03% |
2019 Q4 | 77.1 Million DKK | 3.87% |
2019 Q2 | 9.54 Million DKK | 0.0% |
2018 Q4 | - DKK | 0.0% |
2018 FY | - DKK | 0.0% |
2018 Q1 | - DKK | 0.0% |
2018 Q2 | - DKK | 0.0% |
2018 Q3 | - DKK | 0.0% |
2017 Q2 | - DKK | 0.0% |
2017 FY | - DKK | 0.0% |
2017 Q4 | - DKK | 0.0% |
2017 Q3 | - DKK | 0.0% |
2017 Q1 | - DKK | 0.0% |
2016 Q3 | - DKK | 0.0% |
2016 Q4 | - DKK | 0.0% |
2016 Q1 | - DKK | 0.0% |
2016 FY | - DKK | -100.0% |
2015 FY | 245 Thousand DKK | 0.0% |
2014 FY | 245 Thousand DKK | 24400.0% |
2013 FY | 1000.00 DKK | 0.0% |
Name | Total Debt | Total Debt Difference |
---|---|---|
ALK-Abelló A/S | 765 Million DKK | 100.0% |
Bavarian Nordic A/S | 145.3 Million DKK | 100.0% |
Genmab A/S | 770 Million DKK | 100.0% |
Gubra A/S | 71.43 Million DKK | 100.0% |
Novo Nordisk A/S | 27 Billion DKK | 100.0% |
Pharma Equity Group A/S | 30.22 Million DKK | 100.0% |
Zealand Pharma A/S | 200.27 Million DKK | 100.0% |